Eli Lilly and Company (NYSE:LLY) Trading Down 0%

Eli Lilly and Company (NYSE:LLY) shares dropped 0% during mid-day trading on Monday . The company traded as low as $885.31 and last traded at $891.65. Approximately 1,621,635 shares were traded during trading, a decline of 47% from the average daily volume of 3,080,591 shares. The stock had previously closed at $891.68.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. Guggenheim raised their price objective on shares of Eli Lilly and Company from $855.00 to $884.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Morgan Stanley reissued an “overweight” rating and set a $1,023.00 price target on shares of Eli Lilly and Company in a research report on Friday, July 5th. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Berenberg Bank lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their target price for the company from $725.00 to $1,025.00 in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $948.29.

Eli Lilly and Company Stock Performance

The stock’s fifty day simple moving average is $873.64 and its two-hundred day simple moving average is $800.31. The company has a market cap of $884.21 billion, a price-to-earnings ratio of 136.49, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the transaction, the insider now directly owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,214,704 shares of company stock valued at $1,066,841,316. Company insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Everpar Advisors LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $1,845,000. International Assets Investment Management LLC lifted its holdings in Eli Lilly and Company by 5.3% in the 4th quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock worth $7,343,000 after buying an additional 632 shares in the last quarter. Tennessee Valley Asset Management Partners purchased a new position in Eli Lilly and Company in the 4th quarter valued at about $181,000. SVB Wealth LLC grew its stake in shares of Eli Lilly and Company by 2.3% during the fourth quarter. SVB Wealth LLC now owns 16,304 shares of the company’s stock valued at $9,504,000 after acquiring an additional 362 shares in the last quarter. Finally, Peirce Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $259,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.